Solifenacin succinate for the treatment of overactive bladder

Bibliography

• Abrams P, Cardozo L, Fall M, et al. The standardization of terminology of lower urinary tract function: report from the Standardization Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78
   PubMed Web of Science ®Google Scholar
• Cartwright R, Renganathan A, Cardozo L. Current management of Overactive Bladder. Curr Opin Obstetrics Gynecol 2008;20(5):p489-95. Lippincott, Williams, & Wilkins
   PubMed Web of Science ®Google Scholar
• FDA prescribing information. Revised July 2007. Glasko Smith Kline. Astellas pharma US Inc
   Google Scholar
• Ohtake A, Saitoh C, Yuyama H, et al. Pharmacological characteristics of a new antimuscarinic agent, Solifenacin succinate, in comparison with other antimuscarinic agents. Biol Pharm Bull 2007;30(1):54-8
   PubMed Web of Science ®Google Scholar
• Kobayahsi S, Ikeda K, Miyata K. Comparison of in vitro selectivity profiles of Solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca+2 mobilization study in monkey cells. Life Sci 2004;74(7):843-53
   PubMed Web of Science ®Google Scholar
• Okutsu H, Noguchi Y, Ohtake A, et al. Effects of intravenously and orally administered Solifenacin succinate (YM905) on carbachol-induced intravesical pre3ssure and salivary secretion in mice. Biol Pharm Bull 2007;30(12):2324-7
   PubMed Web of Science ®Google Scholar
• Masunga K, Yoshida M, Inadome A, et al. Phamacological effects of Solifenacin on human isolated urinary bladder. Pharmacology 2008;82(1):43-52
   PubMed Web of Science ®Google Scholar
• Kuipers M, Smulders R, Krauwinkel W, Hoon T. Open label study of the safety and pharmacokinetics of Solifenacin in subjects with hepatic impairment. J Pharmacol Sci 2006;102(4):405-12
   PubMed Web of Science ®Google Scholar
• Smulders RA, Smith NN, Krauwinkel WJ, Hoon TJ. Pharmacokinetics, safety and tolerability of Solifenacin in patients with renal insufficiency. J Pharmacol Sci 2007;103(1):67-74
   PubMed Web of Science ®Google Scholar
• Michel MC, Wetterauer U, Vogel M, de la Rosette JJ. Cardiovascular safety and overall tolerability of Solifenacin in routine clinical use: a 12 week, open label, post marketing surveillance study. Drug Saf 2008;31(6):505-14
   PubMed Web of Science ®Google Scholar
• Swaart PJ, Krauwinkel WJ, Smulders RA, Smith NN. Pharmacokinetic effect of ketoconazole on Solifenacin in healthy volunteers. Basic Clin Pharmacol Toxicol 2006;99(1):33-6
   Google Scholar
• Taekema-Roelvink ME, Swart PJ, Kuipers ME, et al. Pharmacokinetic interaction of Solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double blind, placebo controlled study. Clin Ther 2005;27(9):1403-10
   PubMed Web of Science ®Google Scholar
• Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo-controlled trial of the once-daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172:1919-24
   PubMed Web of Science ®Google Scholar
• Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004;93:303-10
   PubMed Web of Science ®Google Scholar
• Chapple CR, Cardozo L, Steers WD, Govier FE. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract 2006;60:1517-8
   Google Scholar
• Brunton S, Kuritzky L. Recent developments in the management of overactive bladder: focus on the efficacy and tolerabiltiy of once daily solifenacin succinate 5 mg. Current Med Res Opin 2005;21(1):71-80
   Web of Science ®Google Scholar
• Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of Solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70
   PubMed Web of Science ®Google Scholar
• Chapple CR, Fianu-Jonsson A, Indig M, et al. Treatment outcomes in the STAR study: a subanalysis of Solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol 2007;52:1195-203
   PubMed Web of Science ®Google Scholar
• Karram M, Toglia M, Serels S, et al. urology on line journal of the societe interantionale D urologue. Treatment with Solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double blind placebo-controlled trial. 10 November 2008
   Google Scholar
• Millard RJ, Halaska M. Efficacy of Solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis. Curr Med Res Opin 2006;22(1):41-8
   PubMed Web of Science ®Google Scholar
• Nabi G, Cody JD, Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006;(4) Art. No.:CD003781. DOI: 10.1002/14651858.CD003781.pub2
   Google Scholar
• Wagg A, Wyndaile JJ, Sieber P. Efficacy and tolerability of Solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006;4:14-24
   PubMedGoogle Scholar
• Tune LE. Anticholinergic effects of medication in the elderly. J Clin Psychiatry 2001;62(Suppl 21):11-14
   PubMed Web of Science ®Google Scholar
• Novara G, Galfana A, Secco S, et al. A systematic review and meta analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 2008;54(4):740-64
   PubMed Web of Science ®Google Scholar
• Garely AD, Kaufman JM, Sand PK, et al. Symptom bother and health related quality of life outcomes following Solifenacin treatment for overactive bladder: the VESIcare Open Label Trial. Clin Ther 2006;28(11):1935-46
   PubMed Web of Science ®Google Scholar
• Garely AD, Lucente V, Vapnek J, Smith N. Solifenacin for overactive bladder with incontinence: symptom bother and health related quality of life outcomes. Ann Pharmacother 2007;41(3):391-8
   PubMed Web of Science ®Google Scholar
• Kelleher CJ, Cardozo L, Chapple CR, et al. Improved quality of life in patients with overactive bladder symptoms treated with Solifenacin. BJU Int 2005;95(1):81-5
   PubMed Web of Science ®Google Scholar